Buprenorphine Injectable Opioid Abuse Treatment: Will REMS Prevent Misuse?
Executive Summary
US FDA worries Indivior's formulation in prefilled syringes could lead to adverse events if patients obtain direct access; advisory committee to consider if REMS requiring administration by healthcare providers is adequate.
You may also be interested in...
Indivior's Once-Monthly Buprenorphine Clears US FDA With Box Warning, REMS
Launch targeted for first quarter 2018 at price of $1,580 per monthly dose. Post-market requirements include study of 300 mg dose and use as initial treatment. Indivior also following health outcomes.
Indivior's Monthly Injectable Buprenorphine Wins Panel Backing; US FDA May Limit Dosage
Advisory committee votes 18 to 1 for approval of the opioid abuse disorder treatment with restricted distribution; members advise post-market studies, registry.
Braeburn's Buprenorphine Candidate Faces Safety Gauntlet At US FDA Panel
Unlike its potential competitor Indivior, Braeburn didn't submit a proposed REMS for its subcutaneous opioid abuse treatment, but if approved, both buprenorphine candidates will probably end up with similar risk management restrictions.